Questcor (QCOR) Higher as Analyst Sees Continued Acthar Coverage Based on Efficacy

Shares are Questcor Pharmaceuticals (NASDAQ: QCOR) are higher following positive comments from Piper Jaffray analyst David Amsellem. The analyst said benefits of Acthar in nephrotic syndrome (NS) adds to the growing evidence of efficacy which increases odds payers will continue to cover treatment.

Concerns about Acthar for MS continue, the analyst also said.

The firm maintained a Neutral rating and price target of $43.00

For an analyst ratings summary and ratings history on Questcor Pharmaceuticals click here. For more ratings news on Questcor Pharmaceuticals click here.

Shares of Questcor Pharmaceuticals are up 3 percent to $20.97.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
• Amphenol (APH) PT Raised to $130 at Evercore ISI, Remains Top Pick
• Summit Insights Downgrades Silicon Labs (SLAB) to Hold, 'expect its stock to be an inline performer'